Cadrenal Therapeutics announced the appointment of Dr. Lee Scott Golden, M.D., to its Board of Directors.
Dr. Golden brings over 25 years of industry experience in clinical development, particularly in cardiovascular medicine and anticoagulation.
Cadrenal's mission is to deliver safer and more predictable anticoagulant options for patients with unmet needs.
Dr. Lee Golden's Appointment
Dr. Golden appointed as an independent director with extensive experience in cardiovascular medicine.
Company's Focus
Cadrenal aims to provide novel anticoagulation therapies for patients with complex cardiovascular conditions.
Clinical-Stage Assets
Cadrenal's current assets include tecarfarin and frunexian, targeting chronic and acute anticoagulation needs.
- Dr. Golden's expertise enhances Cadrenal's strategic direction in clinical programs and regulatory pathways.
- The appointment reinforces Cadrenal's commitment to advancing tecarfarin and broader pipeline for better anticoagulant treatment options.
The addition of Dr. Lee Golden to Cadrenal's Board signifies a significant step towards advancing anticoagulation therapies for patients with complex cardiovascular conditions.